Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting.
MetadataShow full item record
The 2011 annual meeting of the Children's Tumor Foundation, the annual gathering of the neurofibromatosis (NF) research and clinical communities, was attended by 330 participants who discussed integration of new signaling pathways into NF research, the appreciation for NF mutations in sporadic cancers, and an expanding pre-clinical and clinical agenda. NF1, NF2, and schwannomatosis collectively affect approximately 100,000 persons in US, and result from mutations in different genes. Benign tumors of NF1 (neurofibroma and optic pathway glioma) and NF2 (schwannoma, ependymoma, and meningioma) and schwannomatosis (schwannoma) can cause significant morbidity, and there are no proven drug treatments for any form of NF. Each disorder is associated with additional manifestations causing morbidity. The research presentations described in this review covered basic science, preclinical testing, and results from clinical trials, and demonstrate the remarkable strides being taken toward understanding of and progress toward treatments for these disorders based on the close interaction among scientists and clinicians.
Place of Publication
The following license files are associated with this item:
Showing items related by title, author, creator and subject.
Hanemann, CO; Blakeley, JO; Nunes, FP; Robertson, K; Stemmer-Rachamimov, A; Mautner, V; Kurtz, A; Ferguson, M; Widemann, BC; Evans, DG; Ferner, R; Carroll, SL; Korf, B; Wolkenstein, P; Knight, P; Plotkin, SR; REiNS International Collaboration (United States, 2016-08-16)OBJECTIVE: Clinically validated biomarkers for neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis (SWN) have not been identified to date. The biomarker working group's goals are to (1) define biomarker ...
Ferner, RE; Shaw, A; Evans, DG; McAleer, D; Halliday, D; Parry, A; Raymond, FL; Durie-Gair, J; Hanemann, CO; Hornigold, R; Axon, P; Golding, JF (GermanyGermany, 2014-05)Advances in molecular biology have resulted in novel therapy for neurofibromatosis 2-related (NF2) tumours, highlighting the need for robust outcome measures. The disease-focused NF2 impact on quality of life (NFTI-QOL) ...
Hanemann, CO; Wolters, PL; Martin, S; Merker, VL; Tonsgard, JH; Soloman, SE; Baldwin, A; Bergner, AL; Walsh, K; Thompson, HL; Gardner, KL; HIngtgen, CM; Schorry, E; Dudley, WN; Franklin, B (2016-08-16)